Health TrialsbyHealthPanel

Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients

ConditionsMoyamoya DiseaseMoyamoya
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity Hospital Tuebingen

About this trial

Aim of this study is to improve patient care in Moyamoya Patients by improving Imaging technologies and aiming to identify factors involved in disease progression.

Main tasks are:

* Analysis of CO2-triggered BOLD fMRI for analysis of cerebral hemodynamics in comparison to H2 15O PET/CT * Analysis of longitudinal changes of contrast enhancement in vessel-wall imaging and correlation of disease activity with biosampling * Definition of a standardized recommendation for pre- and postoperative imaging of Moyamoya patients

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients with suspicion of Moyamoya Disease

Patients able to understand the study and to give their informed consent

Disqualifiers

Cerebral vascular disease caused by atherosclerosis

Vasculitis

Contraindications to MRI

Contraindications to PET/CT

Trial design

Design model

Single group

Treatments tested in this trial

  • MRI

    Diagnostic test

    Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.

  • H2 15O PET/CT

    Diagnostic test

    Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images

  • Biosampling

    Other intervention

    Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Moyamoya patientsExperimental treatment 3 interventions
Group B: Control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Value of CO2-triggered BOLD MRI compared to PET/CT

Analysis of comparability of fMRI-based vasoreactivity and PET/CT based vasoreserve (Signal change in percent)

Time frame
From enrollment until maximum of 24 months

Secondary outcomes

1

Vessel-Wall contrast enhancement

Analysis of vessel-wall contrast enhancement as predictor for disease-activity (Intensity of contrast enhancement relative to reference tissue on MRI)

Time frame
From enrollment until maximum of 24 months
2

Circulating endothelial cells

FACS-based analysis of circulating endothelial cells as indicator for disease activity (absolute number of respective circulating endothelial cells subgroup)

Time frame
From enrollment to a maximum of 24 months
3

PCR-based virus sampling

Analysis of possible virus infections as indicator for disease etiology (absolute number of Virus DNA based on PCR results)

Time frame
From enrollment until maximum 24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital Tuebingen

Lead sponsor

University Hospital Freiburg

Collaborator

Source ClinicalTrials.gov
Apply now